Latest From ShangPharma Corp.
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
China’s healthcare sector was back to actively raising proceeds from the capital markets in March and April, which witnessed more than 20 IPOs in total, with a stream of other listings being planned.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Parent & Subsidiaries
- ShangPharma Corp.
- Senior Management
Michael Xin Hui, Chmn. & CEO
William Dai, CFO
Jennifer He , VP, Fin.
Yajun Xu, PhD, SVP, Corp. Dev.
Art Taveras, PhD, Pres. & CSO
- Contact Info
Phone: (86) 21 5132 0088
998 Halei Rd., Zhangjiang Hi-Tech Park
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.